Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIJATC)

• Drug Name: Benzphetamine Drug Info
• Synonyms: Benzaphetamine; Benzfetamina; Benzfetamine; Benzfetaminum; Benzofetamina; Benzphetaminum; Benzylamphetamine; Benzfetamina [DCIT]; Benzfetamina [Spanish]; Benzfetaminum [Latin]; U 0441; Benzfetamina [INN-Spanish]; Benzfetamine (INN); Benzfetamine [INN:BAN]; Benzfetaminum [INN-Latin]; Benzofetamina [INN-Spanish]; Benzphetaminum [INN-Latin]; D-Benzphetamine; Didrex (TN); N-Benzylmethamphetamin; N-Benzyl-N,alpha-dimethylphenethylamine; N,alpha-Dimethyl-N-(phenylmethyl)benzeneethanamine; D-N-Methyl-N-benzyl-beta-phenylisopropylamine; N,alpha-Dimethyl-N-(phenylmethyl)-benzeneethanamine; N-Benzyl-N-methyl-1-phenyl-2-propanamine; N-benzyl-N-methyl-1-phenylpropan-2-amine; N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine; Benzeneethanamine, N,alpha-dimethyl-N-(phenylmethyl)-, (+)-(9CI); (+)-N,alpha-dimethyl-N-(phenylmethyl)-benzeneethanamine; (+)-N-benzyl-N,alpha-dimethylphenethylamine; (+)-benzphetamine; (2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine; (R,S)-N-Benzyl-alpha,N-dimethylphenethylamin; (S)-(+)-N-benzyl-N,alpha-dimethylphenethylamine; (S)-(+)-benzphetamine; (S)-benzphetamine; (alphaS)-N,alpha-dimethylphenethylamine

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Approved	[1]

• Cross-matching ID:
  PubChem CID: 5311017
  ChEBI ID: CHEBI:3044
  CAS Number: CAS 156-08-1
  TTD Drug ID: DMIJATC
  INTEDE Drug ID: DR0198
  ACDINA Drug ID: D00063

Molecule-Related Drug Atlas

Drug(s) Targeting N-methyl-D-aspartate receptor (NMDAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Glutamic Acid	DM4PUDW	Schizophrenia	6A20	Approved	[7]
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[8]
Ketamine	DMT5HA4	Anaesthesia	9A78.6	Approved	[9]
Felbamate	DM1V5ZS	Epilepsy	8A60-8A68	Approved	[10]
Memantine	DMD9WSC	Alzheimer disease	8A20	Approved	[11]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[12]
Levorphanol	DMGS80V	Pain	MG30-MG3Z	Approved	[13]
Magnesium Sulfate	DMVEK07	Acute pain	MG31	Approved	[14]
Magnesium	DMU4ORS	Ischemic stroke	8B11.5Z	Approved	[15]
Orphenadrine	DMW542E	Parkinson disease	8A00.0	Approved	[16]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[17]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[18]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[19]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[20]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[21]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[22]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[23]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[24]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[18]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[25]

Drug(s) Metabolized By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[26]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[27]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[28]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[29]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[30]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[31]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[32]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[33]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[34]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[35]

Drug(s) Metabolized By NADPH-cytochrome P450 reductase (CPR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[36]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[37]
Nitrofurantoin	DM7PQIK	Urinary tract infection	GC08	Approved	[38]
Tacrolimus	DMZ7XNQ	Graft-versus-host disease	4B24	Approved	[39]
Nilutamide	DMFN07X	Prostate cancer	2C82.0	Approved	[40]
Menadiol sodium diphosphate	DMP9N85	Coagulation defect	3B10.0	Approved	[41]
Amrubicin	DM6SGUB	Small-cell lung cancer	2C25.Y	Phase 3	[42]
Nitrobenzodiazepine	DM254EW	N. A.	N. A.	Investigative	[43]

Drug(s) Metabolized By Docosahexaenoic acid omega-hydroxylase (CYP4F11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[6]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[6]
Ethylmorphine	DM0YROF	Discovery agent	N.A.	Investigative	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
N-methyl-D-aspartate receptor (NMDAR)	TT9IK2Z	NOUNIPROTAC	Antagonist	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[3]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[4]
NADPH-cytochrome P450 reductase (CPR)	DE3N2FM	NCPR_HUMAN	Substrate	[5]
Docosahexaenoic acid omega-hydroxylase (CYP4F11)	DEIZLTN	CP4FB_HUMAN	Substrate	[6]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
• [3] Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75.
• [4] Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling. Drug Metab Dispos. 2009 Apr;37(4):745-52.
• [5] On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem. 1985 Jul 15;260(14):8397-403.
• [6] Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
• [7] Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
• [8] How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
• [9] Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
• [10] Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
• [11] The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
• [12] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [13] Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
• [14] Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
• [15] Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
• [16] Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35.
• [17] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [18] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [19] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [20] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [21] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [22] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [23] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [24] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [25] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [26] Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
• [27] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [28] Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
• [29] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [30] Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
• [31] Drugs that may have potential CYP2B6 interactions.
• [32] Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
• [33] Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
• [34] PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
• [35] Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
• [36] Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75.
• [37] Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicin. Can J Physiol Pharmacol. 1999 Aug;77(8):589-97.
• [38] Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med. 2008 Mar 15;44(6):1169-79.
• [39] Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet Genomics. 2017 Sep;27(9):337-346.
• [40] Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen. Biochem Pharmacol. 1992 Feb 4;43(3):654-7.
• [41] Creatinine sulfate/esculoside/hesperidin methyl chalcone/menadiol sodium phosphate/tranexamic acid actions.
• [42] Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica. 2005 Dec;35(12):1121-33.
• [43] Flavin-containing reductase: new perspective on the detoxification of nitrobenzodiazepine. Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):967-81.